Polyclonal Antibody to AKT1/AKT2/AKT3 (phospho-Tyr315/316/312), Rabbit

Artikelnummer: ABI-35-1301-50
Artikelname: Polyclonal Antibody to AKT1/AKT2/AKT3 (phospho-Tyr315/316/312), Rabbit
Artikelnummer: ABI-35-1301-50
Hersteller Artikelnummer: 35-1301-50
Alternativnummer: ABI-35-1301-50-50UL
Hersteller: Abeomics
Wirt: Rabbit
Kategorie: Antikörper
Applikation: IF, IHC, WB
Spezies Reaktivität: Human, Mouse, Rat
Immunogen: Peptide sequence around phosphorylation site of tyrosine 315/316/312 (P-E-Y(p)-L-A) derived from Human AKT1/AKT2/AKT3.
Alternative Synonym: RAC-PK-alpha|| Protein kinase B
General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI3K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at Ser-939 and Thr-1462, thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. /General protein kinase capable of phosphorylating several known proteins. IGF-1 leads to the activation of AKT3, which may play a role in regulating cell survival. Capable of phosphorylating several known proteins. Truncated isoform 2/PKB gamma 1 without the second serine phosphorylation site could still be stimulated but to a lesser extent. Nelms K, et al. (1999) Annu Rev Immunol. 17:701-738. Malabarba M G, et al. (1996) Biochem. J. 319:865-872. Hou J, et al. (1994) Science. 265:1701-1706. Quelle F W, et al. (1995) Mol Cell Biol. 15: 3336-3343.
Klonalität: Polyclonal
NCBI: 207
UniProt: P31749
Formulierung: Purified
Target-Kategorie: AKT1/AKT2/AKT3 (phospho-Tyr315/316/312)
Application Verdünnung: Predicted MW: 60kd, Western blotting: 1:500~1:1000, Immunohistochemistry: 1:50~1:100, Immunofluorescence: 1:100~1:200